Tempus AI and Daiichi Sankyo partnered to apply multimodal AI—using Tempus foundation models including PRISM2—to improve patient selection for an oncology antibody-drug conjugate (ADC) program. Under the agreement, Daiichi Sankyo gains access to Tempus models and AI expertise focused on biomarker discovery, patient stratification, and better benchmarking of control arms for future clinical trials.